期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

口服抗凝药物在血液透析并发房颤患者治疗中的应用进展 被引量：4

下载PDF
导出
摘要 目的:了解口服抗凝药物(OACs)在血液透析并发房颤患者治疗中的临床研究进展。方法:查阅近年来国内、外相关文献,对OACs的作用机制和药动学特征、血液透析并发房颤患者应用OACs进行抗凝治疗的临床研究进行归纳和总结。结果:新型OACs(达比加群、利伐沙班、阿派沙班)比华法林药动学特征更稳定。尽管OACs被推荐用于预防房颤患者卒中的发生,但目前仍缺乏大型的随机、对照和前瞻性研究,以及血液透析并发房颤患者应用OACs的经验和证据。达比加群、利伐沙班和阿哌沙班等与华法林相比,显示出较大优势,为血液透析并发房颤患者的抗凝治疗带来新的选择。
作者 黄凯鹏 高翔 刘淑珍 陈杰
机构地区 中山大学附属第一医院药学部
出处 《中国药房》 CAS 北大核心 2016年第17期2443-2446,共4页 China Pharmacy
关键词 口服抗凝药物 血液透析 房颤 卒中 不良反应
分类号 R973.2 [医药卫生—药品]
  • 相关文献

参考文献38

  • 1Atar I,Konas D,Acikel S,et al.Frequency of atrial fibrillation and factors related to its development in dialysis patients[J].Int J Cardiol,2006,106(1):47.
  • 2Vázquez E,Sánchez-Perales C,Borrego F,et al.Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis[J].Am Heart J,2000,140(6):886.
  • 3Sood MM,Komenda P,Sood AR,et al.The intersection of risk and benefit:is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?[J].Chest,2009,136(4):1 128.
  • 4Salim I,Al Suwaidi J,Ghadban W,et al.Anticoagulation in atrial fibrillation and co-existent chronic kidney disease:efficacy versus safety[J].Expert Opin Drug Saf,2013,12(1):53.
  • 5刘晓,崔一民.新型抗凝血药物——利伐沙班[J].中国药房,2010,21(1):83-86. 被引量：21
  • 6O’Dell KM,Igawa D,Hsin J.New oral anticoagulants for atrial fibrillation:a review of clinical trials[J].Clin Ther,2012,34(4):894.
  • 7San TR,Chan MYY,Siong TW,et al.Stroke prevention in atrial fibrillation:understanding the new oral anticoagulants dabigatran,rivaroxaban,and apixaban[J].Thrombosis,2012,doi:10.1155/2012/108983.
  • 8Dogliotti A,Paolasso E,Giugliano RP.Novel oral anticoagulants in atrial fibrillation:a meta-analysis of large,randomized,controlled trials vs warfarin[J].Clin Cardiol,2013,36(2):61.
  • 9Miller CS,Grandi SM,Shimony A,et al.Meta-analysis of efficacy and safety of new oral anticoagulants(dabigatran,rivaroxaban,apixaban)versus warfarin in patients with atrial fibrillation[J].Am J Cardiol,2012,110(3):453.
  • 10Hart RG,Eikelboom JW,Ingram AJ,et al.Anticoagulants in atrial fibrillation patients with chronic kidney disease[J].Nat Rev Nephrol,2012,8(10):569.

二级参考文献18

  • 1Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2- oxo-3-[4- (3-oxomorpholin-4-yl) phenyl]-1, 3-oxa- zolidin-5-yl}methyl) thiophene-2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[J]. Med Chem, 2005,48 ( 19 ) : 5 900.
  • 2Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban : An oral direct inhibitor of factor Xa[J].Am J Health Syst Pharm, 2008,65(16) : 1 520.
  • 3Perzbom E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct factor Xa inhibitor[J].J Thromb Haemost, 2005, 3(3) :514.
  • 4Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J].Clin Pharmacol Ther, 2005, 78(4) :412.
  • 5Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects[J].Eur J Clin Pharmacol, 2005, 61 (12):873.
  • 6Gerotziafas GT, Elalamy I, Depasse F, et al.In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban[J].J Thromb Haemost, 2007, 5(4) :886.
  • 7Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) : the ODIXa- DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study[J].Circulation, 2007,116( 2 ) : 180.
  • 8Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J].J Thromb Haemost, 2006, 4( 1 ) : 121.
  • 9Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59- 7939), for thromboprophylaxis after total hip replacement [J].Circulation, 2006, 114(22) : 2 374.
  • 10Turpie AG, Fisher WD, Bauer KA, et aI.BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II doseranging study[J].J Thromb Haemost, 2005, 3(11):2 479.

共引文献20

同被引文献45

引证文献4

二级引证文献12

中国药房
2016年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部